Retatrutide is one of the most talked about compounds in metabolic research right now — and for good reason. Developed by Eli Lilly under the code name LY3437943, it represents a significant step forward in the understanding of how multiple hormone receptor pathways can be targeted simultaneously to produce meaningful metabolic outcomes in research settings.
This post provides an overview of what retatrutide is, how it works, and what the current research landscape looks like as of 2026. All information is presented strictly for educational and research purposes.
What Is Retatrutide?
Retatrutide is a novel synthetic molecule and triple agonist activating the glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon receptors simultaneously. PubMed This triple receptor activation is what distinguishes it from earlier generation compounds like semaglutide, which targets only the GLP-1 receptor.
By engaging all three pathways at once, retatrutide produces a broad metabolic response that researchers have found particularly interesting in the context of obesity, metabolic dysfunction, and related conditions.
The TRIUMPH Clinical Trial Programme
The TRIUMPH clinical development programme evaluates retatrutide's safety and efficacy concurrently for the treatment of obesity and two related complications — obstructive sleep apnoea and knee osteoarthritis. PubMed Central
As of early 2026, the TRIUMPH-4 trial has reported top-line results, with the remaining trials expected to report throughout 2026, including TRIUMPH-1 — the largest general obesity trial — and TRIUMPH-2 covering type 2 diabetes. Retaweightloss
Key Findings From Phase 3 Research
The TRIUMPH-4 results announced in December 2025 drew significant attention from the research community. Patients in the Phase 3 TRIUMPH-4 trial on a 12mg dose lost an average of 28.7% of their body weight at 68 weeks BioSpace — figures described by analysts as the strongest efficacy reported to date in obesity research.
Retatrutide also reduced cardiovascular risk markers including non-HDL cholesterol and systolic blood pressure, and more than one in eight retatrutide-treated patients were completely free from knee pain at the end of the study period. Eli Lilly and Company
Research Dosing and Titration
In clinical trials, participants initiated treatment at 2mg once weekly and increased the dose in a stepwise approach every four weeks until reaching target doses of 9mg or 12mg. Eli Lilly and Company Gradual titration is considered essential given the compound's potent triple-agonist mechanism.
Safety Profile in Research
Common side effects observed in TRIUMPH-4 included nausea at 43%, diarrhea at 33%, vomiting at 21%, and dysesthesia at 20.9% — consistent with the GLP-1 class of compounds. BioSpace
Current Status
Retatrutide is currently being evaluated across 19 clinical trials spanning three Phase 3 programmes — TRIUMPH for obesity, TRANSCEND for type 2 diabetes, and SYNERGY for liver disease. An NDA submission to the FDA and MAA to the EMA for the obesity indication is planned pending positive Phase 3 results. Retatrutide
For Research Purposes Only
BioSupply UK supplies retatrutide as a research grade compound strictly for laboratory and in-vitro scientific research. All products are independently third party lab tested, HPLC verified, and supplied at 99%+ purity. Certificates of Analysis are available on request.
This content is intended for informational and research purposes only. Retatrutide is not approved for human use and should not be used outside of a controlled laboratory research setting.